EMAIL THIS PAGE TO A FRIEND

mBio

Methicillin-resistant Staphylococcus aureus adaptation to human keratinocytes.


PMID 25900653

Abstract

Skin is the most common site of Staphylococcus aureus infection. While most of these infections are self-limited, recurrent infections are common. Keratinocytes and recruited immune cells participate in skin defense against infection. We postulated that S. aureus is able to adapt to the milieu within human keratinocytes to avoid keratinocyte-mediated clearance. From a collection of S. aureus isolated from chronically infected patients with atopic dermatitis, we noted 22% had an agr mutant-like phenotype. Using several models of human skin infection, we demonstrate that toxin-deficient, agr mutants of methicillin-resistant S. aureus (MRSA) USA300 are able to persist within keratinocytes by stimulating autophagy and evading caspase-1 and inflammasome activation. MRSA infection induced keratinocyte autophagy, as evidenced by galectin-8 and LC3 accumulation. Autophagy promoted the degradation of inflammasome components and facilitated staphylococcal survival. The recovery of more than 58% agr or RNAIII mutants (P < 0.0001) of an inoculum of wild-type (WT) MRSA from within wortmannin-treated keratinocytes compared to control keratinocytes reflected the survival advantage for mutants no longer expressing agr-dependent toxins. Our results illustrate the dynamic interplay between S. aureus and keratinocytes that can result in the selection of mutants that have adapted specifically to evade keratinocyte-mediated clearance mechanisms. Human skin is a major site of staphylococcal infection, and keratinocytes actively participate in eradication of these pathogens. We demonstrate that methicillin-resistant Staphylococcus aureus (MRSA) is ingested by keratinocytes and activates caspase-1-mediated clearance through pyroptosis. Toxin-deficient MRSA mutants are selected within keratinocytes that fail to induce caspase-1 activity and keratinocyte-mediated clearance. These intracellular staphylococci induce autophagy that enhances their intracellular survival by diminishing inflammasome components. These findings suggest that S. aureus mutants, by exploiting autophagy, can persist within human keratinocytes.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1305642
ANTI-APG5 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
PRS2287
Anti-ASC antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
A0731
Anti-ATG5 (C-terminal) antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody
A0856
Anti-ATG5 (N-terminal) antibody produced in rabbit, affinity isolated antibody, PBS solution
GW22210F
Anti-ATG5 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB3500448
Anti-ATG5 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
HPA042973
Anti-ATG5 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
PRS2511
Anti-NOD2 (ab1) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
PRS2513
Anti-NOD2 (ab2) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB1409648
Anti-NOD2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA041985
Anti-NOD2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1411251
Anti-NOD2 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1409150
Anti-PYCARD antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV37320
Anti-PYCARD antibody produced in rabbit, IgG fraction of antiserum
SAB1407378
Anti-PYCARD, (N-terminal) antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
D4008
Dansylcadaverine, ≥97% (TLC)
C17H25N3O2S
30432
Dansylcadaverine, BioReagent, suitable for fluorescence, ≥99.0% (HPLC)
C17H25N3O2S
RAB0273
Human IL-1 β ELISA Kit, for serum, plasma, cell culture supernatant and urine
RAB0279 Human IL-1 sRI ELISA Kit, for serum, plasma, cell culture supernatant and urine
RAB0280 Human IL-1 sRII ELISA Kit, for serum, plasma, cell culture supernatant and urine
EMU038061 MISSION® esiRNA, esiRNA targeting mouse Atg5 (esiRNA1)
EHU085781 MISSION® esiRNA, esiRNA human ATG5 (esiRNA1)
WH0009474M1
Monoclonal Anti-ATG5 antibody produced in mouse, clone 3D2, purified immunoglobulin, buffered aqueous solution
A2859
Monoclonal Anti-ATG5 antibody produced in mouse, clone ATG5-18, purified immunoglobulin, buffered aqueous solution
SAB1404726
Monoclonal Anti-ATG5, (C-terminal) antibody produced in mouse, clone 1C4, purified immunoglobulin, buffered aqueous solution
RAB0274
Mouse IL-1 β ELISA Kit, for serum, plasma and cell culture supernatant
RAB0275
Mouse IL-1 β ELISA Kit, for cell and tissue lysates
RAB0277
Rat IL-1 β ELISA Kit, for serum, plasma and cell culture supernatant
RAB0278
Rat IL-1 β ELISA Kit, for cell and tissue lysates